Next Article in Journal
Institutional Practices Drive Antibiotic Variability in Neonatal Intensive Care Units: Baseline Evidence to Inform National Stewardship Interventions in Oman
Previous Article in Journal
Policy Framework and Barriers in Antimicrobial Consumption Monitoring at the National Level: A Qualitative Study from Pakistan
Previous Article in Special Issue
Use of Cefiderocol for Carbapenem-Resistant Gram-Negative Infections in Hospital at Home: Multicentric Real-World Experience
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Antibiotics
Volume 15
Issue 1
10.3390/antibiotics15010090
antibiotics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Clinical Outcomes of Bloodstream Infections in Liver Transplant Recipients: A Ten-Year Single-Center Retrospective Analysis, from Türkiye

by
Selda Aydin
1,*,
Meyha Sahin
1,
Bahadir Ceylan
1,
Tunahan Abali
2,
Safa Arda Akin
2,
Murat Dayangac
3 and
Ali Mert
1
1
Department of Infectious Diseases and Clinical Microbiology, Medical Faculty, Istanbul Medipol University, Istanbul 34080, Turkey
2
İnternational Medical School, Istanbul Medipol University, Istanbul 34214, Turkey
3
Center for Organ Transplantation, Istanbul Medipol University Hospital, Istanbul 34810, Turkey
*
Author to whom correspondence should be addressed.
Antibiotics 2026, 15(1), 90; https://doi.org/10.3390/antibiotics15010090
Submission received: 22 November 2025 / Revised: 8 January 2026 / Accepted: 13 January 2026 / Published: 16 January 2026
(This article belongs to the Special Issue Multidrug-Resistant Gram-Negative Bacteria Infections: Current Epidemiology, Prognosis and Treatment Options)
Browse Figures
Versions Notes

Abstract

Background/Objectives: Infections remain a leading cause of morbidity and mortality following liver transplantation, with bloodstream infections (BSIs) representing one of the most critical complications. This study aimed to identify factors associated with mortality in liver transplant recipients who developed BSIs over a 10-year period. Methods: This retrospective study was conducted at a tertiary university hospital between 1 April 2014 and 31 December 2024. A total of 467 adult patients underwent liver transplantation during the study period. Among 467 patients, a total of 210 bloodstream infection episodes occurring in 136 patients were included in the study. Results: BSIs occurred in 29.1% (136/467) of patients, with a total of 210 episodes. The median age was 55 years (IQR: 45–63). Most transplants (95.2%) were from living donors. Hepatitis B virus infection (27.1%) was the most common underlying etiology of cirrhosis. The majority of BSIs (61.2%) occurred within the first three months post-transplant. A total of 242 pathogens were isolated, with ESBL-producing Enterobacterales identified in 72.6% and carbapenem-resistant Enterobacterales (CRE) in 30.1% of cases. Notably, carbapenem resistance among Klebsiella spp. was high at 51.78%. The overall mortality rate was 14.28%. Multivariate analysis identified that a high Pitt Bacteremia Score (hazard ratio [HR] 1.502, 95% confidence interval [CI] 1.361–1.657, p < 0.001) and CRE infection (HR 3.644, 95% CI 1.380–9.620, p = 0.009) were independent predictors of mortality. Conclusions: BSIs are a significant post-transplant complication with high antimicrobial resistance. The Pitt bacteremia score is a strong predictor of mortality and may guide early risk stratification and clinical management in liver transplant recipients.

1. Introduction

Liver transplantation (LT) has markedly improved survival and quality of life among patients with end-stage liver disease. Despite these advances, infectious complications—especially during the early post-transplant period and under intense immunosuppressive therapy—remain a leading cause of morbidity and mortality [1,2]. Bloodstream infections (BSIs) are among the most severe infectious complications following LT and represent the leading cause of infection-related mortality in liver transplant recipients (LTRs) [3]. Recent studies over the last decade have reported the incidence of BSIs in LTRs to range from 20.6% to 29.1%, with Gram-negative bacilli (GNB) being the leading pathogens, accounting for 52–58% of cases [4,5]. Mortality rates associated with BSIs vary widely, ranging from 10% to 52%, depending on host-related factors, causative microorganisms, and the appropriateness of antimicrobial therapy [3]. Early diagnosis and prompt initiation of effective antimicrobial treatment are therefore crucial and can be lifesaving in this setting [6].
However, the rising prevalence of antimicrobial resistance in recent years has increasingly complicated the management of BSIs and has been associated with poorer clinical outcomes [3,4]. In particular, BSIs caused by extended-spectrum beta-lactamase (ESBL)-producing microorganisms and carbapenem-resistant Enterobacterales (CRE) have been linked to significantly higher mortality rates among bacteremic patients [7,8]. CRE have emerged as a major clinical concern in BSIs, as they substantially limit therapeutic options and are associated with adverse outcomes [9,10].
This challenge is particularly relevant in Türkiye, which holds the highest rate of living organ donation worldwide and has seen a consistent upward trend in transplant volume, with over 21,000 procedures performed between 2009 and 2024 [11,12]. However, national data also indicate a concerning prevalence of multidrug-resistant pathogens (52.7%) and high infection-related mortality (35.9%) in this population [13,14,15].
Given the high incidence of BSIs, the increasing antimicrobial resistance, and the significant impact of BSIs on survival after LT, it is crucial to understand the factors associated with patient outcomes. Therefore, the aim of this retrospective study was to identify independent predictors of mortality among LTRs who developed BSI at a tertiary care university hospital in Türkiye.

2. Results

2.1. Characteristics of BSI Episodes

During the study period, a total of 467 patients underwent LT surgery. BSI occurred in 29.1% (N = 136/467) of patients. A total of 210 episodes were documented during the study period. Figure 1 illustrates the annual distribution of transplantations performed and BSI episodes. The overall mortality rate per BSI episode was 14.3% (N = 30/210). The median age of patients at the time of BSI episode was 55 years (interquartile range [IQR]: 45–63). The median post-transplant follow-up period was 553 days (IQR: 166–1207), and the median hospital stay following a bacteremia episode was 34 days (IQR: 19.5–51). Table 1 illustrates the demographic, clinical and laboratory characteristics of BSI episodes.
The most prevalent comorbidities were diabetes mellitus (DM) (46.6%), chronic kidney disease (CKD) (15.9%), and coronary artery disease (CAD) (14.4%). A comparison of survivors and non-survivors in terms of comorbidities revealed no statistically significant difference. The most common etiology of cirrhosis was hepatitis B virus (HBV) infection, 27.1%, followed by hepatitis C virus (HCV) infection and metabolic dysfunction-associated steatohepatitis (MASH), 10.5%, and alcohol-related liver disease (ALD), 7.1%. The majority of the LT (95.2%) were performed via living donors. Post-transplant complications were commonly ascites, bile leakage and pneumonia, with percentages of 25.7%, 17.1% and 12.4%, respectively (Table 1).

2.2. Source of BSI

Among a total of 210 BSI episodes, the rate of primary bacteremia was identified as 23.8% (n = 50). Of all BSI episodes, 61.2% (128/210) occurred within the first three months post-transplant. The most common sources of infection in secondary bacteremia were intra-abdominal infections (52.4%, n = 110/210), catheter-related bacteremia (21%, n = 44/210), pyelonephritis (2.4%, n = 5/210), and pneumonia (1%, n = 2/210) (Table 1). Bacteremia secondary to intra-abdominal infections occurred as a consequence of either organ/space surgical site infections or cholangitis. Among catheter-related bloodstream infections, staphylococci were responsible for 43.2% of the causative pathogens, while GNBs accounted for 47.7%. Of the staphylococcal isolates, 76.9% were methicillin-resistant. Prior CRE colonization was identified in 17.6% of patients who developed CRE bacteremia. CRE bacteremia occurred more frequently in colonized patients than in non-colonized patients (26.1% vs. 11.4%); however, the association was not statistically significant (p = 0.141).

2.3. Microbiological Findings

Polymicrobial growth was observed in 16.7% (35/210) of BSI episodes. Of these polymicrobial infections, 65.7% comprised either two distinct Enterobacterales species or combinations involving enterococci, while nonfermentative-GNB were present in 28.6% of cases. A total of 242 bacterial and fungal pathogens were isolated from blood cultures. Most common pathogen was Klebsiella spp. (23.1%), followed by E. coli (22.3%). Among Enterobacterales isolates, 72.6% were Extended-spectrum β-lactamase–producing Enterobacterales (ESBL-E), while 30.1% were carbapenem-resistant Enterobacterales (CRE). The CRE rate was 7.4% (4/54) in E. coli isolates and 51.78% (29/56) in Klebsiella spp. isolates. Carbapenem resistance was found in 38.8% (7/18) of Pseudomonas spp. and in 50% (4/8) of Acinetobacter spp. isolates. Among Gram-positive microorganisms, Enterococcus spp. was the most frequently isolated species, accounting for 13.2% (32/242) of total isolates. In candidemia cases, the predominant species was Candida albicans, with a total of 20 Candida spp. isolated. Table 2 summarizes the overall distribution of microbial agents isolated from blood cultures, while Figure 2 details this distribution on a year-by-year basis.

2.4. Outcomes

The overall 30-day mortality rate was 14.3% after the onset of a BSI episode. Mortality in patients with CRE bacteremia was 23.5% (n = 8/34). Several factors were found to be significantly associated with mortality in LTRs with BSI in the univariate analysis, including cadaveric donor type, a higher Pitt bacteremia score, lower platelet and lymphocyte count, elevated total bilirubin levels, AKI, length of hospital stay and CRE infection (p < 0.05). Although early-onset bacteriemia episodes were more likely to have a fatal course, this difference did not reach statistical significance. In contrast, MASH was found to be associated with a high survival rate. However, in multivariable Cox regression model revealed that the Pitt Bacteremia Score (hazard ratio [HR] 1.502, 95% confidence interval [CI] 1.361–1.657, p < 0.001) and CRE infection (HR 3.644, 95% CI 1.380–9.620, p = 0.009) were independent predictors of mortality. The results of the multivariate analysis of factors associated with mortality are presented in Table 3.

3. Discussion

In this single-center retrospective cohort study investigating BSIs after LT, the incidence of BSI was 29.1%, with GNB accounting for 64.8% of isolates. The prevalence of ESBL-E and CRE was notably high, at 72.6% and 30.1%, respectively. The 30-day mortality rate was 14.3%. Among evaluated risk factors, a high Pitt bacteremia score and CRE infection emerged as independent predictors of mortality.
The execution of head-to-head comparisons with earlier studies is difficult because of differences in geographical locations, study periods, and the types of solid organ transplants included. Most published studies have focused on BSI following SOT, regardless of the type of organ transplanted. The incidence rate in our cohort lies within the range reported in previous investigations, which vary between 11.3% and 39.4% among liver transplant recipients [4,5,16,17,18,19,20]. Our incidence was lower than that documented by Yeşilkaya et al. in a national Turkish cohort [5] but higher than the rates reported by Neofytos et al. in the United States and by Adelman et al. in Switzerland [18,20]. Similar infection frequencies have been reported in studies from South Korea (Kim et al.), China (Wan et al.), Italy (Barchiesi et al.), and France (Bert et al.), suggesting a globally consistent burden of post-transplant BSIs [4,16,17,19]. The 14.3% mortality observed in our study also aligns with previously published data, which reported rates between 14.7% and 19.4% [18,20,21,22,23].
Few large-scale studies have focused exclusively on BSIs in liver transplant recipients [4,19,22]. In these large cohorts and other investigations, septic shock, prolonged mechanical ventilation, AKI, and the requirement for hemodialysis following transplantation were identified as major predictors of death [16,17,22,24,25]. We observed that a higher Pitt bacteremia score—reflecting severe infection and the need for intensive care support [26]—was the strongest predictor of mortality, consistent with findings from Santos et al. [22] and Zhang et al. [24]. The present study lends further support to the hypothesis that the Pitt bacteremia score is an effective tool for the assessment of the clinical severity of BSIs.
The global rise in antimicrobial resistance further complicates the management of these infections. According to surveillance data from the Centers for Disease Control and Prevention in the United States and Europe for 2021–2023, the prevalence of CRE varies between 2.8–17.6% and 0–69.7%, respectively [27,28]. Turkish national surveillance reports even higher rates, approaching 55% [29]. In this context, the 30.1% CRE rate observed in our study—particularly the 51.8% resistance rate among Klebsiella isolates—represents a serious clinical concern. BSIs due to multidrug-resistant GNB have been consistently associated with limited therapeutic options, increased early mortality, and prolonged hospital stays in transplant populations [30,31,32,33,34]. In the present study, we found that CRE infection significantly increased mortality risk (HR: 3.64, 95% CI: 1.38–9.62). This observation highlights the pressing need for strict infection control measures, early screening, and stewardship programs to mitigate the impact of antimicrobial resistance.
In non-liver transplant populations, the prevalence of CRE among BSIs has been reported to range between 14.3% and 21.6%, with mortality rates of 36.7–56.9% [35,36,37,38]. In contrast, our cohort demonstrated a higher CRE prevalence (30.1%) but a lower mortality rate. Previous studies focusing on solid organ transplant (SOT) recipients have shown that LTRs constitute more than half of CRE BSI cases [34,39]. Besides their increased susceptibility to CRE infections, outcomes in LTRs may be substantially influenced by effective infection control practices and antimicrobial stewardship. Variations in CRE prevalence and mortality reported across studies may reflect multifactorial influences, such as host factors, immunosuppression intensity, clinical severity, comorbidity burden, early diagnosis, source control, and availability of appropriate antimicrobial therapy.
Lymphopenia, an indicator of impaired adaptive immunity, has been linked to worse outcomes in critically ill and post-transplant patients [40]. Although lymphocyte and platelet counts, elevated bilirubin levels, and cadaveric donor type were all associated with mortality in univariate analysis, these variables did not retain statistical significance in multivariable modeling. This discrepancy may reflect differences in patient population, sample size, or the interplay of other dominant risk factors in our cohort.
Despite the varying etiology of BSIs according to study timing and centers, Enterobacterales are the predominant causative agents. In the present study, Enterobacterales were predominant, with a high prevalence of ESBL and CRE production. The relatively lower isolation frequency of non-fermenting GNB in our series suggests that Enterobacterales should remain a primary focus in empirical regimens during the early post-transplant period.

Limitations of Study

Although the inclusion of a relatively large number of BSI events from a single center and the homogeneity of the study population represent important strengths, it is also essential to acknowledge the inherent limitations of this study. First, its retrospective and single-center design may limit the generalizability of the findings, as local epidemiological patterns, antimicrobial stewardship practices, and transplantation protocols may differ across centers.
Secondly, the retrospective design may have resulted in potential missing data due to incomplete records. Thirdly, the characterization of antimicrobial resistance was based on routine phenotypic antimicrobial susceptibility testing. Specific phenotypic confirmatory assays for ESBL production and for carbapenem resistance mechanisms, as well as molecular analyses to identify underlying resistance genes, were not systematically performed during the study period, which limits the epidemiological interpretation of resistance mechanisms. Finally, as with all retrospective analyses, unmeasured confounders cannot be excluded, and prospective multicenter studies are warranted to validate our findings and clarify independent predictors of mortality in this high-risk population.

4. Materials and Methods

4.1. Study Design and Setting

This retrospective cohort study included patients who underwent LT between 1 April 2014 and 31 December 2024 at a 970-bed tertiary university hospital in Türkiye with a dedicated solid organ transplantation (SOT) unit. Clinical data were collected through 30 January 2025 to ensure inclusion of all liver transplantation procedures performed up to 31 December 2024 and to allow complete ascertainment of 30-day mortality following BSI onset, with the latest possible BSI onset date of 31 December 2024 and the latest possible death date of 30 January 2025. This study was approved by the Ethics Committee at Istanbul Medipol University (E-10840098-202.3.02-6355; 19 September 2025) with a waiver of informed consent.

4.2. Study Population

During the study period, 488 LTs were performed in 467 adult patients (≥18 years), including 21 retransplantations. Among 467 patients, a total of 210 bloodstream infection episodes occurring in 136 patients were included in the study.
  • Inclusion criteria
  • Adult recipients (age ≥ 18 years) who underwent liver transplantation at our center during the study period.
  • Availability of core transplant and follow-up data in the electronic medical record.
  • Exclusion criteria
  • Pediatric recipients (<18 years).
  • Multi-organ transplantation (e.g., liver–kidney) and/or intestinal/multivisceral transplantation.
  • Liver transplants performed outside our center with only follow-up at our institution
  • Inadequate documentation to adjudicate BSI status or vital status (e.g., missing transplant date, lack of microbiology data, unknown outcome).
The patient inclusion flow chart is summarized in Figure 3.

4.3. Data Collection

Patient data were collected from the hospital’s electronic health record system. Demographic characteristics (age, sex), comorbidities [chronic obstructive pulmonary disease (COPD), congestive heart failure (CHF), coronary artery disease (CAD), chronic kidney disease (CKD), diabetes mellitus (DM), and malignancy], etiology of cirrhosis, and donor type (living vs. deceased) were recorded.
Post-transplant complications (pneumonia, ascites, bile leakage, thrombosis), reoperations, and re-transplantations were noted. The timing of BSI onset was classified as early (≤3 months) or late (>3 months) after LT. For each BSI episode, the Pitt bacteremia score, presence of acute kidney injury (AKI), length of hospital stay, and relevant laboratory parameters were documented.
Microbiological data included the microorganisms isolated from blood cultures, antimicrobial susceptibility profiles, and rectal colonization with carbapenem-resistant Enterobacterales (CRE) or vancomycin-resistant enterococci (VRE). The presumed infection source was categorized as intra-abdominal infection, catheter-related BSI, urinary tract infection, pulmonary infection, or primary bacteremia. All-cause mortality within 30 days following bacteremia onset was recorded.

4.4. Microbiological Analyses

Blood cultures were routinely obtained from all LTRs with suspected bloodstream infection according to institutional protocols. For each suspected episode, at least two sets of blood cultures (each set consisting of one aerobic and one anaerobic bottle) were collected from separate venipuncture sites prior to the initiation of antimicrobial therapy whenever feasible. Blood culture samples were processed using an automated blood culture system (BacT/ALERT®, bioMérieux, Paris, France), and bottles were incubated for up to five days. Positive blood cultures were subcultured on appropriate agar medium, and microbial identification was performed using conventional biochemical methods and/or matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS; Bruker Daltonics, Bremen, Germany). Antimicrobial susceptibility testing was conducted using automated systems (BD Phoe-nix™, Becton Dickinson, Franklin Lakes, NJ, USA) and/or the disk diffusion method, in accordance with the recommendations of the European Committee on Antimicrobial Susceptibility Testing (EUCAST). Minimum inhibitory concentrations (MICs) were interpreted based on EUCAST clinical breakpoints applicable at the time of isolate recovery [41]. Only microbiologically confirmed bloodstream infection episodes were included in the final analysis.

4.5. Definitions

The definition of BSIs is based on the Centers for Disease Control and Prevention/ National Healthcare Safety Network criteria [42].
Primary Bacteremia: Laboratory-confirmed BSI not secondary to any other infection site.
Secondary Bacteremia: BSI secondary to a defined site-specific infection.
Catheter-Related Bacteremia: Positive blood culture in a patient with a central venous catheter in the preceding 48 h and no other identifiable source.
A BSI episode was defined by the presence of at least one positive blood culture bottle containing a recognized pathogenic microorganism. For microorganisms that are potential skin contaminants (e.g., coagulase-negative staphylococci, Corynebacterium spp., etc.), the isolation of the same microorganism with similar antimicrobial susceptibility profiles from at least two separate blood culture sets was required to confirm a true infection episode.
Multiple isolates of the same microorganism within 14 days were considered part of a single episode; recurrence after 14 days was regarded as a new episode.
Extended-spectrum β-lactamase–producing Enterobacterales (ESBL-E) were phenotypically identified as isolates resistant to penicillins and oxyimino-β-lactam–containing cephalosporins (including cefuroxime, third- and fourth-generation cephalosporins, and aztreonam), while remaining susceptible to cephamycins and carbapenems. Carbapenem resistance was defined by resistance to at least one carbapenem agent (imipenem, meropenem, or ertapenem) based on EUCAST breakpoints [43].
Carbapenem-non-susceptible Pseudomonas aeruginosa (CNSPA): Pseudomonas aeruginosa that has tested either intermediate or resistant to at least one of imipenem, meropenem, or doripenem [44].
Carbapenem-non-susceptible Acinetobacter spp. (CNSA): Any Acinetobacter spp. that has tested either intermediate or resistant to at least one of imipenem, meropenem, or doripenem [44].

4.6. Statistical Analysis

Statistical analyses were performed using SPSS version 22.0 software. The normal distribution of variables was assessed using the Shapiro–Wilk test. Descriptive analyses were presented as means ± standard deviations for normally distributed variables, and as medians (interquartile range-IQR) for non-normally distributed variables. Continuous variables were compared using the Mann–Whitney U test due to the violation of parametric test assumptions, while categorical variables were compared using the Chi-square test and Fisher’s Exact test. Thirty-day mortality following BSI was analyzed on a per-episode basis; repeated episodes from the same patient were not adjusted for clustering. Variables potentially associated with mortality were included in the multivariable Cox regression analysis. To avoid model overfitting, the number of covariates included was restricted according to the rule of at least 10 events per variable. Potential collinearity between variables was assessed, and in cases of overlapping effects, clinically relevant variables were prioritized. Results were reported as odds ratios (OR) with 95% confidence intervals (CI), and a two-sided p < 0.05 was considered statistically significant.

5. Conclusions

BSIs remain a major source of morbidity and mortality after LT. CRE infection and high Pitt bacteremia scores were identified as independent predictors of poor outcomes. Timely diagnosis, prompt initiation of active antimicrobial therapy guided by local resistance patterns, and reinforcement of infection control strategies are crucial for improving survival among liver transplant recipients.

Author Contributions

Conceptualization, S.A.; project administration, S.A.; methodology, S.A. and M.S.; formal analysis, M.S.; investigation, S.A., T.A. and S.A.A.; resources, T.A. and S.A.A.; writing—original draft preparation, S.A.; writing—review and edits A.M., M.D., B.C. and M.S.; validation, A.M., M.D. and B.C.; supervision, A.M., B.C. and M.D. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

This study was carried out in accordance with the ethical standards of the institutional research committee and with the 1964 Declaration of Helsinki and its later amendments, or comparable ethical standards. The ethical approval for this study was obtained from the Ethics Committee at Istanbul Medipol University (E-10840098-202.3.02-6355; 19 September 2025).

Informed Consent Statement

Patient consent was waived due to the retrospective design of the study and the use of anonymized data obtained from the hospital’s electronic medical record system.

Data Availability Statement

The raw data supporting the conclusions of this article will be made available by the authors upon request.

Conflicts of Interest

The authors have no conflicts of interest to declare.

Abbreviations

The following abbreviations are used in this manuscript:
LTLiver transplantation
BSIBloodstream infections
LTRsLiver transplant recipients
GNBGram-negative bacilli
IQRinterquartile range
DMDiabetes mellitus
CKDChronic kidney disease
CADCoronary artery disease
HBVHepatitis B virus
HCVHepatitis C virus
MASHMetabolic dysfunction-associated steatohepatitis
ALDAlcohol-related liver disease
CRECarbapenem-resistant Enterobacterales
VREVancomycin-resistant enterococci
ESBL-EExtended-spectrum β-lactamase–producing Enterobacterales
HRHazard ratio
CIConfidence interval
COPDChronic obstructive pulmonary disease
CHFCongestive heart failure
AKIAcute kidney injury
MRCoNSMethicillin-resistant Coagulase-negative staphylococci
MSSAMethicillin-susceptible Staphylococcus aureus
MRSAMethicillin-resistant Staphylococcus aureus
SOTSolid organ transplantation
OROdds ratios
EUCASTEuropean Committee on Antimicrobial Susceptibility Testing
CNSPACarbapenem-non-susceptible Pseudomonas aeruginosa
CNSACarbapenem-non-susceptible Acinetobacter spp.

References

  1. Baganate, F.; Beal, E.W.; Tumin, D.; Azoulay, D.; Mumtaz, K.; Black, S.M.; Washburn, K.; Pawlik, T.M. Early mortality after liver transplantation: Defining the course and the cause. Surgery 2018, 164, 694–704. [Google Scholar] [CrossRef] [PubMed]
  2. Genovese, C.; Offer, M.; Colaneri, M.; Dore, F.; Montrucchio, G.; Scaglione, G.; Monti, G.; Bandera, A.; Viaggi, B.; Gori, A.; et al. Hospital Acquired Infections Among Solid Organ Transplant Recipients Hospitalized in Intensive Care Unit (2018–2024): A Study of the GiViTI Group. Transpl. Infect. Dis. 2025, 27, e70120. [Google Scholar] [CrossRef]
  3. Kritikos, A.; Manuel, O. Bloodstream infections after solid-organ transplantation. Virulence 2016, 7, 329–340. [Google Scholar] [CrossRef]
  4. Bert, F.; Larroque, B.; Paugam-Burtz, C.; Janny, S.; Durand, F.; Dondero, F.; Valla, D.-C.; Belghiti, J.; Moreau, R.; Nicolas-Chanoine, M.-H. Microbial epidemiology and outcome of bloodstream infections in liver transplant recipients: An analysis of 259 episodes. Liver Transplant. 2010, 16, 393–401. [Google Scholar] [CrossRef] [PubMed]
  5. Yesilkaya, A.; Azap, O.K.; Demirkaya, M.H.; Ok, M.A.; Arslan, H.; Akdur, A. Bloodstream infections among solid organ transplant recipients: Eight years’ experience from a Turkish University Hospital. Balkan Med. J. 2013, 30, 282–286. [Google Scholar] [CrossRef]
  6. De la Rosa-Riestra, S.; Pérez-Crespo, P.M.M.; Rodríguez, M.T.P.; Sousa, A.; Goikoetxea, J.; Iglesias, J.M.R.; Armiñanzas, C.; López-Hernández, I.; López-Cortés, L.E.; Rodríguez-Baño, J. Mortality impact of further delays in active targeted antibiotic therapy in bacteraemic patients that did not receive initial active empiric treatment: Results from the prospective, multicentre cohort PROBAC. Int. J. Infect. Dis. 2024, 145, 107072. [Google Scholar] [CrossRef]
  7. Paniagua-García, M.; Bravo-Ferrer, J.M.; Pérez-Galera, S.; Kostyanev, T.; de Kraker, M.E.; Feifel, J.; Palacios-Baena, Z.R.; Schotsman, J.; Cantón, R.; Carevic, B.; et al. Attributable mortality of infections caused by carbapenem-resistant Enterobacterales: Results from a prospective, multinational case-control-control matched cohorts study (EURECA). Clin. Microbiol. Infect. 2024, 30, 223–230. [Google Scholar] [CrossRef]
  8. Kalpoe, J.S.; Sonnenberg, E.; Factor, S.H.; Martin, J.d.R.; Schiano, T.; Patel, G.; Huprikar, S. Mortality associated with carbapenem-resistant Klebsiella pneumoniae infections in liver transplant recipients. Liver Transplant. 2012, 18, 468–474. [Google Scholar] [CrossRef] [PubMed]
  9. Pérez-Nadales, E.; Fernández-Ruiz, M.; Gutiérrez-Gutiérrez, B.; Pascual, Á.; Rodríguez-Baño, J.; Martínez-Martínez, L.; Aguado, J.M.; Torre-Cisneros, J. Extended-spectrum β-lactamase-producing and carbapenem-resistant Enterobacterales bloodstream infection after solid organ transplantation: Recent trends in epidemiology and therapeutic approaches. Transpl. Infect. Dis. 2022, 24, e13881. [Google Scholar] [CrossRef]
  10. Dumlu, R.; Uyar, N.Y.; Ayaş, M.; Aksoy, N.; Öztürk, N.; Kocagöz, A.S. Investigation of ceftazidime-avibactam susceptibility in clinical isolates of gram-negative bacteria. Turk. J. Med. Sci. 2022, 52, 1839–1844. [Google Scholar] [CrossRef]
  11. Available online: https://www.irodat.org/?p=publications (accessed on 23 December 2025).
  12. Available online: https://organkds.saglik.gov.tr/dss/PUBLIC/Transplant_Solid_Organ.aspx (accessed on 23 December 2025).
  13. Yamazhan, T.; Avsar, C.B.; Zeytunlu, M.; Tasbakan, M.; Sertoz, R.; Zeytinoglu, A.; Aydemir, S.; Unalp, O.; Ergun, O.; Uguz, A.; et al. Infections developing in patients undergoing liver transplantation: Recipients of living donors may be more prone to bacterial/fungal infections. Turk. J. Gastroenterol. 2020, 31, 894–901. [Google Scholar] [CrossRef]
  14. Tezcan, H.; Altunsoy, A.; Gokce, D.T.; Gokcan, H.; Ari, D.; Aydin, O.; Bostanci, E.B.; Kayhan, M.A. Multidrug-Resistant Infections After Liver Transplantation, Etiology and Risk Factors: A Single-Center Experience. Exp. Clin. Transplant. 2023, 21, 952–960. [Google Scholar] [CrossRef] [PubMed]
  15. Ayaz, C.M.; Ceylan, S.; Yılmaz, V.T.; Adanır, H.; Turhan, Ö. Timeline and Incidence of Infectious Complications in Older Transplant Recipients During the First Year Post-Transplantation. Pathogens 2024, 13, 1061. [Google Scholar] [CrossRef] [PubMed]
  16. Barchiesi, F.; Montalti, R.; Castelli, P.; Nicolini, D.; Staffolani, S.; Mocchegiani, F.; Fiorentini, A.; Manso, E.; Vivarelli, M. Carbapenem-Resistant Klebsiella pneumoniae influences the outcome of early infections in liver transplant recipients. BMC Infect. Dis. 2016, 16, 538. [Google Scholar] [CrossRef]
  17. Wan, Q.; Ye, Q.; Ming, Y.; Ma, Y.; Zhou, J.; Qiao, B. The risk factors for mortality in deceased donor liver transplant recipients with bloodstream infections. Transplant. Proc. 2013, 45, 305–307. [Google Scholar] [CrossRef] [PubMed]
  18. Neofytos, D.; Stampf, S.; Hoessly, L.D.; D’asaro, M.; Tang, G.N.; Boggian, K.; Hirzel, C.; Khanna, N.; Manuel, O.; Mueller, N.J.; et al. Bacteremia During the First Year After Solid Organ Transplantation: An Epidemiological Update. Open Forum Infect. Dis. 2023, 10, ofad247. [Google Scholar] [CrossRef]
  19. Kim, S.-H.; Mun, S.J.; Ko, J.-H.; Huh, K.; Cho, S.Y.; Kang, C.-I.; Chung, D.R.; Choi, G.-S.; Kim, J.M.; Joh, J.-W.; et al. Poor outcomes of early recurrent post-transplant bloodstream infection in living-donor liver transplant recipients. Eur. J. Clin. Microbiol. Infect. Dis. 2021, 40, 771–778. [Google Scholar] [CrossRef]
  20. Adelman, M.W.; Connor, A.A.; Hsu, E.; Saharia, A.; Mobley, C.M.; Victor, D.W.; Hobeika, M.J.; Lin, J.; Grimes, K.A.; Ramos, E.; et al. Bloodstream infections after solid organ transplantation: Clinical epidemiology and antimicrobial resistance (2016–2021). JAC Antimicrob. Resist. 2024, 6, dlad158. [Google Scholar] [CrossRef]
  21. Chen, F.; Pang, X.-Y.; Shen, C.; Han, L.-Z.; Deng, Y.-X.; Chen, X.-S.; Zhang, J.-J.; Xia, Q.; Qian, Y.-B. High mortality associated with gram-negative bacterial bloodstream infection in liver transplant recipients undergoing immunosuppression reduction. World J. Gastroenterol. 2020, 26, 7191–7203. [Google Scholar] [CrossRef]
  22. Santos, C.A.; Hotchkiss, R.S.; Chapman, W.C.; Olsen, M.A. Epidemiology of Bloodstream Infections in a Multicenter Retrospective Cohort of Liver Transplant Recipients. Transplant. Direct 2016, 2, e67. [Google Scholar] [CrossRef]
  23. Yalçin, T.Y.; Azap, Ö.; Köse, A.; Bayindir, Y.; Saricaoğlu, E.M.; Çinar, G.; Kizmaz, Y.U.; Kurşun, E.; Alişkan, H.E.; Tekçe, Y.T.; et al. Evaluation of extensively drug-resistant gram-negative bacteremia among solid-organ transplant recipients: A multicenter study. Turk. J. Med. Sci. 2021, 51, 1960–1968. [Google Scholar] [CrossRef]
  24. Zhang, W.; Wang, W.; Kang, M.; Wu, S.; Liu, Y.; Liao, Q.; Xiao, Y.; Ma, Y.; Xie, Y. Bacterial and fungal infections after liver transplantation: Microbial epidemiology, risk factors for infection and death with infection. Ann. Transplant. 2020, 25, e921591. [Google Scholar] [CrossRef] [PubMed]
  25. Kim, H.K.; Park, Y.K.; Wang, H.-J.; Kim, B.W.; Shin, S.Y.; Lim, S.-K.; Choi, Y.H. Epidemiology and clinical features of post-transplant bloodstream infection: An analysis of 222 consecutive liver transplant recipients. Infect. Chemother. 2013, 45, 315–324. [Google Scholar] [CrossRef]
  26. Chang, J.-M.; Lin, K.-H.; Lai, C.-H.; Tsai, I.-T.; Hsu, Y.-C. The Prognostic Role of Pitt Bacteremia Score in Patients with Nonbacteremic Klebsiella pneumoniae Infections. Can. J. Infect. Dis. Med. Microbiol. 2025, 2025, 6780766. [Google Scholar] [CrossRef]
  27. HAI Pathogens & Antimicrobial Resistance Report, 2018–2021. 2021. Available online: https://www.cdc.gov/nhsn/hai-report/index.html (accessed on 26 October 2025).
  28. Surveillance and Disease Data for Antimicrobial Resistance. 2023. Available online: https://www.ecdc.europa.eu/en/about-us/networks/disease-networks-and-laboratory-networks/ears-net-data (accessed on 26 October 2025).
  29. Ulusal Antimikrobiyal Direnç Sürveyans (Uamds) Aği 2022–2023 Yillik Raporu n.d. Available online: https://hsgm.saglik.gov.tr/tr/surveyanslar/uamdss.html (accessed on 23 December 2025).
  30. Santoro-Lopes, G.; De Gouvêa, E.F. Multidrug-resistant bacterial infections after liver transplantation: An ever-growing challenge. World J. Gastroenterol. 2014, 20, 6201–6210. [Google Scholar] [CrossRef]
  31. Martin-Mateos, R.; Martínez-Arenas, L.; Carvalho-Gomes, Á.; Aceituno, L.; Cadahía, V.; Salcedo, M.; Arias, A.; Lorente, S.; Odriozola, A.; Zamora, J.; et al. Multidrug-resistant bacterial infections after liver transplantation: Prevalence, impact, and risk factors. J. Hepatol. 2024, 80, 904–912. [Google Scholar] [CrossRef]
  32. Song, S.; Li, X.; Wan, Q.; Ye, Q. Risk factors for mortality in liver transplant recipients with ESKAPE infection. Transplant. Proc. 2014, 46, 3560–3563. [Google Scholar] [CrossRef] [PubMed]
  33. Rodríguez-Goncer, I.; Ruiz-Arabi, E.; Herrera, S.; Sabé, N.; Los-Arcos, I.; Silva, J.T.; Pérez-Nadales, E.; Machuca, I.; Álvarez, R.; Valerio, M.; et al. Management of multidrug-resistant gram-negative bacilli infections in adult solid organ transplant recipients: GESITRA-IC/SEIMC, CIBERINFEC, and SET recommendations update. Transplant. Rev. 2025, 39, 100937. [Google Scholar] [CrossRef] [PubMed]
  34. Anesi, J.A.M.; Lautenbach, E.M.; Thom, K.A.; Tamma, P.D.M.; Blumberg, E.A.; Alby, K.; Bilker, W.B.; Werzen, A.; Ammazzalorso, A.; Tolomeo, P.; et al. Clinical Outcomes and Risk Factors for Carbapenem-resistant Enterobacterales Bloodstream Infection in Solid Organ Transplant Recipients. Transplantation 2023, 107, 254–263. [Google Scholar] [CrossRef]
  35. Chen, Y.; Huang, J.; Dong, L.; Xu, B.; Li, L.; Zhao, Z.; Li, B. Clinical and genomic characterization of carbapenem-resistant Enterobacterales bloodstream infections in patients with hematologic malignancies. Front. Cell. Infect. Microbiol. 2024, 14, 1471477. [Google Scholar] [CrossRef]
  36. Zhou, C.; Jin, L.; Wang, Q.; Wang, X.; Chen, F.; Gao, Y.; Zhao, C.; Chen, H.; Cao, B.; Wang, H. Bloodstream infections caused by carbapenem-resistant enterobacterales: Risk factors for mortality, antimicrobial therapy and treatment outcomes from a prospective multicenter study. Infect. Drug Resist. 2021, 14, 731–742. [Google Scholar] [CrossRef] [PubMed]
  37. De Pascale, G.; Cortegiani, A.; Rinaldi, M.; Antonelli, M.; Cattaneo, S.; Cecconi, M.; Cuffaro, R.; Dalfino, L.; Di Biase, F.; Donati, A.; et al. Incidence of hospital-acquired infections due to carbapenem-resistant Enterobacterales and Pseudomonas aeruginosa in critically ill patients in Italy: A multicentre prospective cohort study. Crit. Care 2025, 29, 32. [Google Scholar] [CrossRef] [PubMed]
  38. De Araujo, L.G.; Cedeño, K.; Bomfim, A.P.; Silva, M.d.O.; Mendes, A.V.; Barberino, M.G.; Gouveia, E.L.; Bahia, F.M.M.; dos Reis, M.G.; Reis, J.N. Carbapenem-resistant Enterobacterales bloodstream infections related to death in two Brazilian tertiary hospitals. BMC Infect. Dis. 2025, 25, 725. [Google Scholar] [CrossRef]
  39. Taimur, S.; Pouch, S.M.; Zubizarreta, N.; Mazumdar, M.; Rana, M.; Patel, G.; Freire, M.P.; Madan, R.P.; Kwak, E.J.; Blumberg, E.; et al. Impact of pre-transplant carbapenem-resistant Enterobacterales colonization and/or infection on solid organ transplant outcomes. Clin. Transplant. 2021, 35, e14239. [Google Scholar] [CrossRef]
  40. Kitajima, T.; Rajendran, L.; Lisznyai, E.; Lu, M.; Shamaa, T.; Ivanics, T.; Yoshida, A.; Claasen, M.P.; Abouljoud, M.S.; Sapisochin, G.; et al. Lymphopenia at the time of transplant is associated with short-term mortality after deceased donor liver transplantation. Am. J. Transplant. 2023, 23, 248–256. [Google Scholar] [CrossRef] [PubMed]
  41. Available online: https://www.eucast.org/bacteria/clinical-breakpoints-and-interpretation/breakpoints-in-brackets/ (accessed on 24 December 2025).
  42. Bloodstream Infection Event (Central Line-Associated Bloodstream Infection and Non-Central Line Associated Bloodstream Infection). 2025. Available online: https://www.cdc.gov/nhsn/pdfs/pscmanual/4psc_clabscurrent.pdf (accessed on 17 October 2025).
  43. Available online: https://www.eucast.org/bacteria/important-additional-information/resistance-detection/ (accessed on 24 December 2025).
  44. CDC; NCEZID; DHQP. Antimicrobial-Resistant Phenotype Definitions Analysis of Antimicrobial-Resistant Organisms in NHSN; Centers for Disease Control and Prevention: Atlanta, GA, USA, 2022. Available online: https://www.cdc.gov/nhsn/pdfs/ps-analysis-resources/phenotype_definitions.pdf (accessed on 23 December 2025).
Antibiotics 15 00090 g001
Figure 1. Annual distribution of transplantations performed and BSI episodes.
Figure 1. Annual distribution of transplantations performed and BSI episodes.
Antibiotics 15 00090 g001
Antibiotics 15 00090 g002
Figure 2. The distribution of microbial agents obtained from blood cultures by year.
Figure 2. The distribution of microbial agents obtained from blood cultures by year.
Antibiotics 15 00090 g002
Antibiotics 15 00090 g003
Figure 3. Description of the patient populations included in this study.
Figure 3. Description of the patient populations included in this study.
Antibiotics 15 00090 g003
Table 1. Demographic and Clinical Characteristics of BSI episodes in Relation to 30-Day Mortality.
Table 1. Demographic and Clinical Characteristics of BSI episodes in Relation to 30-Day Mortality.
CategorySurvived
N = 180 (85.7%)		Died
N = 30 (14.3%)		Total
N = 210 (100%)		p-Value
(>0.05)
Age (IQR)54 (45–63)57.5 (51–64)55 (45–63)0.282
Sex
Male129 (61.4)17 (8.1)146 (69.5)0.098
Female51 (24.3)13 (6.2)64 (30.5)
Comorbidity
COPD3 (1.4)1 (0.5)4 (1.9)0.442
CHF11 (5.3)3 (1.4)14 (6.7)0.410
DM82 (39.4)15 (7.2)97 (46.6)0.701
Malignity26 (12.5)2 (1)28 (13.5)0.384
CAD24 (11.5)6 (2.9)30 (14.4)0.567
CKD26 (12.5)7 (3.4)33 (15.9)0.167
Etiology of cirrhosis
HBV51 (24.3)6 (2.9)57 (27.1)0.400
HCV19 (9)3 (1.4)22 (10.5)0.640
Alcohol12 (5.7)3 (1.4)15 (7.1)0.442
MASH22 (10.5)0 (0.0)22 (10.5)0.031
Others55 (26.2)11 (5.2)66 (31.4)0.703
Donor type
Living174 (82.9)26 (12.4)200 (95.2) 0.039
Cadaveric6 (2.9)4 (1.9)10 (4.8)
Post-transplant
complications
Pneumonia21 (10.0)5 (2.4)26 (12.4)0.371
Bile leakage31 (14.8)6 (2.9)37 (17.6)0.752
Ascites48 (22.9)6 (2.9)54 (25.7)0.505
Portal vein/hepatic artery thrombosis15 (7.1)2 (1.0)17 (8.1)1.000
Timing of bacteremia 0.069
0–3 months105 (50.2)23 (11)128 (61.2)
>3 months75 (35.7)7 (3.3)52 (24.8)
Pitt bacteremia score0 (0–1)10 (6–12)0 (0–2)0.000
Laboratory findings
Leukocytes (cell/mm3)6970 (4520–12,190)6900 (2770–18,000)6970 (4327–12,777)0.789
Platelets (×103/mm3)113 (69.5–180.5)51 (29–104)105 (60–166.5)0.000
Total bilirubin (mg/dL)1.53 (0.8–3.25)5.8 (2.52–11.4)1.74 (0.89–4.31)0.000
Albumin (g/dL)3.4 (3.09–3.7)3.3 (2.85–3.59)3.4 (3.05–3.7)0.097
C-reactive protein (mg/L)111 (57–180)87.7 (61–142)107 (57–171)0.188
Procalcitonin (ng/mL)4.4 (1.68–50.35)7.6 (3–22.2)5.2 (2–35)0.419
Neutrophil (cell/mm3)5495 (3520–10,245)5370 (2330–11,200)5295 (2270–15,550)0.325
Lymphocyte (cell/mm3)525 (305–830)290 (190–620)275 (160–642.5)0.011
AKI during BSI15 (7.2)12 (5.7)27 (12.9)0.000
Repeated surgery intervention43 (20.8)7 (3.4)50 (24.2)0.911
Re-transplantation18 (8.6)3 (1.4)21 (10.0)1.000
Length of stay in hospital (IQR)36 (20–55)24 (17–36)34 (19.5–51)0.038
Rectal colonization
CRE20 (10.4)3 (1.6)23 (12.1)1.000
VRE10 (5.2)2 (1)12 (6.3)0.671
Polymicrobial BSI29 (13.8)6 (2.9)35 (16.7)0.591
Enterobacteriaceae
ESBL70 (61.9)12 (10.6)82 (72.5)0.488
CRE26 (23.0)8 (7.1)34 (30.1)0.035
Non-fermentative GNB
CRPA4 (26.7)2 (100)6 (35.3) 0.110
CRAB2 (50)3 (75)5 (62.5)1.00
Penicillin resistance28 (71.8)2 (5.1)30 (76.9)0.556
Methicillin resistance18 (69.2)2 (77.7)20 (76.9)1.000
IQR: Interquartile range, COPD: Chronic obstructive pulmonary disease, CHF: Congestive heart failure, CAD: Coronary artery disease, CKD: Chronic kidney disease, DM: Diabetes mellitus, HBV: Hepatitis B virus, HCV: Hepatitis C virus, MASH: Non-alcoholic steatohepatitis, AKI: Acute kidney injury, BSI: Bloodstream infection, ESBL: Extended spectrum beta-lactamase, CRE: Carbapenem-resistant Enterobacterales, VRE: Vancomycin-resistant enterococci, GNB: Gram-negative bacilli, CNSPA: Carbapenem-non-susceptible Pseudomonas aeruginosa, CNSA: Carbapenem-non-susceptible Acinetobacter spp.
Table 2. Microorganisms Isolated from Blood Cultures.
Table 2. Microorganisms Isolated from Blood Cultures.
Microorganisms (Total: 242)No (%)
Enterobacterales121 (50)
Klebsiella spp.56 (23.1)
Escherichia coli54 (22.3)
Enterobacter spp.6 (2.5)
Other Gram-negative5 (2.1)
Non-fermentative GNB36 (14.8)
Pseudomonas spp.18 (7.4)
Acinetobacter spp.8 (3.3)
S. maltophilia10 (4.1)
Gram-positive Cocci65 (26.9)
Enterococcus spp.32 (13.2)
Streptecoccus spp.7 (2.9)
MRCoNS16 (6.6)
MSSA6 (2.5)
MRSA4 (1.7)
Fungi—Candida spp.20 (8.3)
C. albicans9 (3.7)
C. galabrata6 (2.5)
C. tropicalis2 (0.8)
C. kefyr2 (0.8)
C. parapsilosis1 (0.4)
GNB: Gram-negative bacilli, MRCoNS: Methicillin-resistant Coagulase-negative staphylococci, MSSA: Methicillin-susceptible Staphylococcus aureus, MRSA: Methicillin-resistant Staphylococcus aureus.
Table 3. Multivariate Analysis of Factors Associated with Mortality.
Table 3. Multivariate Analysis of Factors Associated with Mortality.
Hazard Ratio (HR)Confidence Interval (CI) 95%p
Pitt bacteremia score1.5021.361–1.6570.000
Total bilirubin1.0170.967–1.0700.520
Lymphocyte count1.0000.999–1.0010.458
CRE infection3.6441.380–9.6200.009
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Aydin, S.; Sahin, M.; Ceylan, B.; Abali, T.; Akin, S.A.; Dayangac, M.; Mert, A. Clinical Outcomes of Bloodstream Infections in Liver Transplant Recipients: A Ten-Year Single-Center Retrospective Analysis, from Türkiye. Antibiotics 2026, 15, 90. https://doi.org/10.3390/antibiotics15010090

AMA Style

Aydin S, Sahin M, Ceylan B, Abali T, Akin SA, Dayangac M, Mert A. Clinical Outcomes of Bloodstream Infections in Liver Transplant Recipients: A Ten-Year Single-Center Retrospective Analysis, from Türkiye. Antibiotics. 2026; 15(1):90. https://doi.org/10.3390/antibiotics15010090

Chicago/Turabian Style

Aydin, Selda, Meyha Sahin, Bahadir Ceylan, Tunahan Abali, Safa Arda Akin, Murat Dayangac, and Ali Mert. 2026. "Clinical Outcomes of Bloodstream Infections in Liver Transplant Recipients: A Ten-Year Single-Center Retrospective Analysis, from Türkiye" Antibiotics 15, no. 1: 90. https://doi.org/10.3390/antibiotics15010090

APA Style

Aydin, S., Sahin, M., Ceylan, B., Abali, T., Akin, S. A., Dayangac, M., & Mert, A. (2026). Clinical Outcomes of Bloodstream Infections in Liver Transplant Recipients: A Ten-Year Single-Center Retrospective Analysis, from Türkiye. Antibiotics, 15(1), 90. https://doi.org/10.3390/antibiotics15010090

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Article metric data becomes available approximately 24 hours after publication online.
Back to TopTop